Research graph
References from Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Local targets link to admitted publications; unresolved targets remain external evidence.
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
10.1016/j.bjhh.2014.10.001 · 2015 · External reference
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis
10.1186/1756-8722-5-2 · 2012 · External reference
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
10.1002/ajh.25230 · 2018 · External reference
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
10.1182/blood-2013-03-488098 · 2013 · External reference
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
2014 · External reference
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
10.1093/annonc/mdv203 · 2015 · External reference
Unresolved reference
2023 · External reference
Defining disease modification in myelofibrosis in the era of targeted therapy
10.1002/cncr.34205 · 2022 · External reference
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
10.1056/nejmoa1110556 · 2012 · External reference
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
10.1038/leu.2016.148 · 2016 · External reference
How I treat myelofibrosis after failure of JAK inhibitors
10.1182/blood-2018-02-785923 · 2018 · External reference
Definition and management of ruxolitinib treatment failure in myelofibrosis
10.1038/bcj.2014.84 · 2014 · External reference
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL
10.1371/journal.pone.0114363 · 2015 · External reference
Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
10.1111/jcmm.15730 · 2020 · External reference
BCL2A1 is expressed in myelofibrosis specimens and JAK2-mutated UKE-1 cells, yet does not inhibit synergistic cell killing by BCL-XL inhibitor navitoclax plus JAK1/2 inhibitors, including ruxolitinib [abstract]
10.1158/1538-7445.am2022-5339 · 2022 · External reference
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor
10.1158/0008-5472.can-07-5836 · 2008 · External reference
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors
10.1016/j.celrep.2013.10.038 · 2013 · External reference
Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy
10.1200/jco.21.02188 · 2022 · External reference
Guidelines from the International Conference on Harmonisation (ICH)
10.1016/j.jpba.2005.02.037 · 2005 · External reference
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
10.1002/cncr.26129 · 2011 · External reference
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
10.1016/j.leukres.2009.01.035 · 2009 · External reference
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
10.1182/blood-2009-09-245837 · 2010 · External reference
European Consensus on grading bone marrow fibrosis and assessment of cellularity
2005 · External reference
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
10.1182/blood-2015-03-633404 · 2015 · External reference
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
10.1182/bloodadvances.2017009530 · 2017 · External reference
New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: focus on clinical development of BCL-X(L) /BCL-2 inhibition with navitoclax
10.1002/cncr.34986 · 2023 · External reference
Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial
10.1001/jamaoncol.2017.5818 · 2018 · External reference
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
10.1016/s2352-3026(17)30237-5 · 2018 · External reference
S195: MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor
10.1097/01.hs9.0000843672.56808.41 · 2022 · External reference
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
10.1016/s2352-3026(22)00116-8 · 2022 · External reference
Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis
2023 · External reference
Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
10.1007/s00277-017-3194-4 · 2018 · External reference
Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
10.1002/cncr.32664 · 2020 · External reference
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
10.1056/nejmoa1110557 · 2012 · External reference
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
10.3324/haematol.2014.115840 · 2015 · External reference
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
10.1002/ajh.25777 · 2020 · External reference
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
10.1182/blood-2017-05-783225 · 2017 · External reference
A phase 3, open-label, randomized study evaluating the efficacy and safety of navitoclax plus ruxolitinib versus best available therapy in patients with relapsed/refractory myelofibrosis (TRANSFORM-2)
10.1182/blood-2020-139247 · 2020 · External reference
